A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy

In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.

Related Videos
Chandler H. Park, MD, an expert on renal cell carcinoma
Edward B. Garon, MD, MS, an expert on lung cancer